<p>Biopharma firm Biocon said on Wednesday it will raise funds worth up to $527.3 million) via issue of securities, which may include debt and selling shares to institutional investors. </p><p>Recently, Biocon Biologics had inked a settlement and licensing pact with Regeneron, paving the way to commercialise its biosimilar product Yesafili in the US.</p>
<p>Biopharma firm Biocon said on Wednesday it will raise funds worth up to $527.3 million) via issue of securities, which may include debt and selling shares to institutional investors. </p><p>Recently, Biocon Biologics had inked a settlement and licensing pact with Regeneron, paving the way to commercialise its biosimilar product Yesafili in the US.</p>